MMP-9 (Matrix Metalloproteinase-9)

TEST: 500124
Test number copied
CPT: 83520
Print Share

Synonyms

  • Matrix Metalloproteinase-9

Expected Turnaround Time

3 - 7 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

For more information, please view the literature below.

Procedures for Hemostasis and Thrombosis: A Clinical Test Compendium

Specimen Requirements

Specimen

Serum, frozen

Volume

1 mL

Minimum Volume

0.5 mL

Container

Gel-barrier tube

Collection

Transfer serum to a plastic transport tube before freezing. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions

Freeze. Stable at room temperature for 30 minutes.

Test Details

Limitations

Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

Methodology

Enzyme-linked immunosorbent assay (ELISA)

Reference Interval

0−983 ng/mL

Additional Information

MMP-9 is a marker of inflammation, tissue remodeling, wound healing, and mobilization of tissue-bound growth factors and cytokines. Its expression correlates with abnormal collagen deposition accompanying pancreatic cancer, with lymph node metastasis in breast cancer and with regional vessel invasion by giant cell tumor or bone. MMP-9 contributes to the pathogenesis of numerous clinical disease states, including rheumatic arthritis, coronary artery disease, chronic obstructive pulmonary disease, multiple sclerosis, asthma, and cancer. Current research is exploring the role of this enzyme as a potential drug target.

References

Gress TM, Müller-Pillasch F, Lerch MM, Friess H, Büchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer. 1995 Aug 9; 62(4):407-413.7635566
John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001; 7(1):14-23.11349215
Muroski MG, Roycik MD, Newcomer RG, et al. Matrix metalloproteinase-9/gelatinase B Is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008 Feb; 9(1):34-46.18289055

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
500124 MMP-9 (Matrix metalloprot.-9) 500125 MMP9 ng/mL 60243-3